Neurolieve Biosciences Ltd’s Post

The importance of choosing the right iPSC line cannot be overstated when developing a successful therapeutic product! Selecting the ideal induced pluripotent stem cell (iPSC) line is a critical step in ensuring the effectiveness and safety of regenerative therapies. At Lindville Bio (www.lindvillebio.com), we understand the complexities of iPSC-based therapies and are here to assist with every crucial decision throughout your product development journey. From selecting the right iPSC line to ensuring regulatory compliance, our expert team offers tailored guidance to help you create breakthrough therapies with confidence. Learn more about the challenges and opportunities in iPSC therapies at #AdvancedTherapiesEurope https://lnkd.in/ete3AA2v and visit us at www.lindvillebio.com for personalized support in your development process! #iPSC #RegenerativeMedicine #AdvancedTherapies #LindvilleBio #Biotech #StemCellTherapies #Phacilitate

🗸 Milestone Unlocked! We are thrilled to announce a pivotal achievement in Cytonics' journey. Our recent submission of the Phase 1 clinical trials protocol to ClinicalTrials.gov marks the commencement of an exhilarating phase in our mission to revolutionize osteoarthritis treatment. This submission is not just a procedural step; it represents years of dedicated research and development, bringing us closer to our first-in-human Phase 1 clinical trial. 🔗 Learn more about our R&D and investment opportunity: invest.cytonics.com The upcoming Phase 1 study is a testament to our team's expertise and dedication. It also underscores our potential to significantly impact the biotechnology sector. As we progress into this new phase, your continued support and investment become even more crucial. The success of this trial will not only elevate our company's standing in the industry but also pave the way for delivering life-changing therapies to the 600M suffering from osteoarthritis. 🌍 A New Era Of Healthcare  We are on the cusp of a new era in biotechnology, and your investment plays a vital role in this journey. By backing our initiative, you are not just investing in a company; you are investing in a future where debilitating diseases like osteoarthritis can be eradicated. Join us in this exciting phase of growth and innovation! Together, we are not just making strides in healthcare; we are making history. #biotechnology #drugdevelopment #arthritis #clinicaltrials #crowdfunding

🗸 Milestone Unlocked! We are thrilled to announce a pivotal achievement in Cytonics' journey. Our recent submission of the Phase 1 clinical trials protocol to ClinicalTrials.gov marks the commencement of an exhilarating phase in our mission to revolutionize osteoarthritis treatment. This submission is not just a procedural step; it represents years of dedicated research and development, bringing us closer to our first-in-human Phase 1 clinical trial. 🔗 Learn more about our R&D and investment opportunity: invest.cytonics.com The upcoming Phase 1 study is a testament to our team's expertise and dedication. It also underscores our potential to significantly impact the biotechnology sector. As we progress into this new phase, your continued support and investment become even more crucial. The success of this trial will not only elevate our company's standing in the industry but also pave the way for delivering life-changing therapies to the 600M suffering from osteoarthritis. 🌍 A New Era Of Healthcare  We are on the cusp of a new era in biotechnology, and your investment plays a vital role in this journey. By backing our initiative, you are not just investing in a company; you are investing in a future where debilitating diseases like osteoarthritis can be eradicated. Join us in this exciting phase of growth and innovation! Together, we are not just making strides in healthcare; we are making history. #biotechnology #drugdevelopment #arthritis #clinicaltrials #crowdfunding

My Bioelectronic Wrap of 2023 🚀 Exciting times in biotechnology! ( I Know I usually talk about psychedelic breakthroughs, but that's not the only science I follow! ) This video encapsulates the groundbreaking advancements in medicine and biotech in 2023, especially in the realms of Alzheimer's treatment and genetic disorders. I'll be keeping an eye on this sector; it's close to my heart. 🧬 Featuring: Eisai US Co., Ltd. & Biogen Inc. (LEQEMBI) Vaxxinity (UB-311) Vertex Pharmaceuticals & CRISPR Therapeutics (Casgevy) 🌟 Notable Mentions: Tivic Health Setpoint.io Medical Sky Medical Technology Cala Health Boston Consulting Group (BCG) Scientific Corporation Abbott Laboratories Medtronic BIOTRONIK SE & Co. KG Cochlear Ltd. These companies are at the forefront of bioelectronic innovation, shaping a future where medicine and technology converge to offer unprecedented solutions in healthcare. #Biotechnology #MedicalInnovation #Healthcare #Bioelectronics #AlzheimersTreatment #CRISPR #2023InReview #digitaltwin #aiavatar

🔬 Exciting News in Biomedical Innovation! 🚀 We proudly announce the successful patent grant for our groundbreaking invention titled "ANGIOGENIN AS A DIAGNOSTIC OR PROGNOSTIC BIOMARKER AND DRUG TARGET IN AGE-RELATED MACULAR DEGENERATION"! This breakthrough work identifies angiogenin as a pivotal biomarker with significant diagnostic and prognostic potential in Age-Related Macular Degeneration (AMD) and establishes it as a promising drug target, opening doors to novel therapeutic interventions. Kudos to our dedicated team whose unwavering commitment to advancing healthcare has led to this remarkable achievement. This patent marks a significant step in redefining the landscape of AMD diagnostics and treatment, underscoring our organization's commitment to making a positive impact on global health. Stay tuned for further updates on our journey towards transforming lives through biomedical innovation! #BiomedicalInnovation #AMD #HealthcareBreakthrough #MedicalResearch #Innovation #PatentGranted #ScientificAdvancement #MedicalScience 🌐👩🔬👨🔬

Earlier this year, Amylyx faced a setback when Relyvrio was withdrawn after a failed Phase III trial for ALS. Despite this, the company has shown resilience, revealing promising results in other areas and securing a strategic acquisition. 💪 Relyvrio shows potential in improving pancreatic function and glycemic control in Wolfram syndrome, and Amylyx recently acquired avexitide, a GLP-1 receptor antagonist, for $35.1 million. This aligns with their strategy to tackle high-impact, rare diseases. 📈 Amylyx remains focused on neurological diseases, continuing pivotal trials for AMX0035 in progressive supranuclear palsy and developing AMX0114 for ALS. With a strong pipeline, Amylyx is poised for potentially highly impactful future🌐 #Biotech #Innovation #Healthcare

Developing photoresponsive milk-derived exosomes for oral delivery: in this article, Man Kyu Shim, Yoosoo Yang at KIST(Korea Institute of Science and Technology) and collaborators explored the potential of milk-derived exosomes as a noninvasive approach to overcome treatment barriers, enabling effective photodynamic therapy for glioblastoma https://lnkd.in/eX9DHZWz Their study highlighted the potential of milk exosomes as oral drug delivery vehicles to the brain, improving patient convenience and therapeutic efficacy. An article also authored by Jiwoong Choi, HoChung Jang, Daeho Park, Byeongmin Park, Yeongji Jang, Sangmin Lee and Sun Hwa Kim #Extracellularvesicles #exosomes #milk #glioblastoma #BBB #Vesiculab

The Lifetime Achievement winner has been announced - and what a story! Listen to Dame Carol Robinson, whose pioneering work in mass spectrometry has paved the way for a healthier future, there's a little gem in those few seconds, about how at first, she had doubts about her surprising results. I guess this is normal in science, when things don't behave as expected, the first thing you do is check that everything is in order, make sure that the results are "real". Recognised as our Lifetime Achievement winner, her patented inventions serve as a beacon of hope in the fight against various diseases.    🔗 inventoraward.org     #InventorAward #Healthcare #MedTech #Inventors #BigIdeas #Patents #WomenInSTEM #WomenInTech #WomenInScience

"NTI has proven in Phase II trials that its product is safer and just as effective as Neuren’s product for treating Rett Syndrome... With $11.6M in the bank and solid clinical data, NTI is ready to find partners that can take its product to the next level."   Neurotech International Ltd (ASX:NTI) is entering a pivotal phase, transitioning from clinical trials to securing strategic partnerships. With positive Phase II results for NTI164 across three neurological disorders, NTI is now well-positioned to seek global partners to advance its product into the US, Europe, and Asia.   As the biotech industry witnesses billion-dollar deals, NTI's progress could lead to significant market opportunities. Read the latest Investment Memo by Next Investors for more info: https://lnkd.in/gSpq9YZK   #NeurotechInternational #Biotech #ASX #InvestmentNews #ClinicalTrials #NeurologicalDisorders #NTI164 #DealMaking #PharmaPartnerships #OrphanDrug #NTI

“How much funding does The Kidney Project need to complete its work?” We estimate that we need roughly USD 10 million over the next 3-4 years to complete preclinical development of the implantable bioartificial kidney and request approval for human studies. If the funding goals are not met, the timeline for the completion of the device could be extended. It is critical that we secure larger funding commitments that will allow us to take the necessary steps necessary to scale up our device for human clinical trials. Once we reach the clinical trial stage, we are optimistic that support from private investors and industry partners will enable us to complete the commercialization process. The least we all can do is spread the word to reach the right resources. Find out more by visiting The Kidney Project’s FAQ page: https://lnkd.in/gspy3hiV To give: bit.ly//Givetokidney Facebook: ArtificialKidney Instagram/Threads: @ArtificialKidney Twitter: @KidneyProject YouTube: TheKidneyProject #TheKidneyProject #kidneydisease #ckd #dialysis #bioartificialkidney #kidneytransplant #transplant #ESRD #medicine #translationalscience #science #donor #technology #tech #innovation #invention #newtechnologies #techtrends #technews #techlife #bioengineering #health #kidneyhealth